Mesothelioma Clinical Trials: Eligibility May Be Too Strict, Study Finds
A new Australian study suggests that too many people are being left out of mesothelioma clinical trials under current trial rules. The researchers say that eligibility requirements around pleural mesothelioma studies are too strict. The result is that many people never have the opportunity to take advantage of investigational treatments only available through studies. In addition, the trial data gathered may not really apply to average mesothelioma patients. The Australian researchers are calling for changes that will let more people qualify for mesothelioma clinical trials. What Are Mesothelioma Clinical Trials? Pleural mesothelioma is an intractable cancer of the lining around the lungs. People who get it usually worked in an industry that exposed them to asbestos. Once asbestos gets in … Continue reading Mesothelioma Clinical Trials: Eligibility May Be Too Strict, Study Finds
Phase 3 Clinical Trial to Test Durvalumab for Mesothelioma
A potential new first-line immunotherapy treatment for mesothelioma is now recruiting patients for a phase 3 clinical trial. The trial will compare the immunotherapy drug durvalumab (IMFINZI) combined with chemotherapy against chemotherapy alone. Results from the phase 2 trials of this combination released last year were promising. Tests showed that it extended mesothelioma survival by about 8 months with no debilitating side effects. The randomized phase 3 clinical trial will try to confirm these results in a larger group of people. Mesothelioma Treatment with Durvalumab Durvalumab is an immune checkpoint inhibitor. Immune checkpoint inhibitors deactivate a cancer cell survival mechanism that helps cancer cells evade the immune system. Pleural mesothelioma and other types of cancer use proteins like PD-1 to … Continue reading Phase 3 Clinical Trial to Test Durvalumab for Mesothelioma
Exercise Unlikely to Prevent Mesothelioma Development
A new Australian study suggests that exercise is unlikely to prevent mesothelioma development in people who have been exposed to asbestos. The study focused on asbestos-exposed mice. Asbestos cancer can take decades to develop. Researchers thought the long latency period might offer an opportunity to prevent mesothelioma development with physical activity. But even mice that had no mesothelioma symptoms were less likely than mice their same age to be physically active. How Mesothelioma Develops Over Time Malignant mesothelioma has one of the longest latency periods of any cancer. The latency period is the time between exposure to a carcinogen and development of the disease. Scientists know that asbestos can cause mesothelioma. But they have not found a way to prevent … Continue reading Exercise Unlikely to Prevent Mesothelioma Development
Immune Checkpoint Inhibitor May Change the Standard Treatment of Malignant Pleural Mesothelioma
The immune checkpoint inhibitor durvalumab could become a standard part of first-line mesothelioma treatment if the results of a new study hold true in a Phase 3 trial. Australian researchers have become the latest to show the benefit of adding durvalumab to first-line chemotherapy for pleural mesothelioma. Chemotherapy is usually the first thing doctors use to treat pleural mesothelioma. But as many as half of mesothelioma patients do not respond to it. Researchers around the world are hopeful that adding an immune checkpoint inhibitor like durvalumab will lead to better response rates. What is an Immune Checkpoint Inhibitor? Mesothelioma cells survive and thrive in part because they have ways of protecting themselves. Chemotherapy drugs are less likely to hurt them … Continue reading Immune Checkpoint Inhibitor May Change the Standard Treatment of Malignant Pleural Mesothelioma
Low Dose Aspirin Could Increase Mesothelioma Risk
If you are at risk for malignant mesothelioma, you may want to think twice about taking low dose aspirin on a regular basis. A new study suggests that low dose aspirin could speed up the growth and spread of cancer cells in older people. The study appears in the Journal of the National Cancer Institute. It involved more than 19,000 people in Australia and the US. Low Dose Aspirin and Mesothelioma Many older people take small daily doses of aspirin to reduce their risk for heart attack. Aspirin reduces inflammation and the blood’s ability to clot. This makes it less likely to form the blockages that cause heart attacks and strokes. But mounting evidence suggests that taking low dose aspirin … Continue reading Low Dose Aspirin Could Increase Mesothelioma Risk
Quality of Life with Mesothelioma: Too Many Symptoms, Not Enough Support
A new study suggests that even the healthiest patients have a lower quality of life with mesothelioma than they should. That is because they tend to have many symptoms and needs that are not being met. Researchers at Sir Charles Gairdner Hospital in Western Australia ran the study. They used data from the RESPECT-Meso trial. RESPECT-Meso was a multicenter, randomized study to measure the impact of early palliative care on quality of life with mesothelioma. Australia has one of the highest per capita rates of malignant mesothelioma in the world. Researchers found that the high symptom burden of this cancer is a big problem for patients. Many also said they were not getting the information they need from their doctors. … Continue reading Quality of Life with Mesothelioma: Too Many Symptoms, Not Enough Support
First-Line Immunotherapy May Be Better Than Chemo for This Mesothelioma Subtype
A new study suggests that people with sarcomatoid mesothelioma may fare better if they have first-line immunotherapy before considering chemotherapy. Chemotherapy is the standard first-line treatment for most people with mesothelioma. But a report in the journal Translational Lung Cancer questions the wisdom of that trend. The study focused on the outcomes of patients with the sarcomatoid mesothelioma subtype. These patients lived longer after immunotherapy than patients with other subtypes. When first-line immunotherapy worked best, patients produced more white blood cells. Researchers say these patients might do well to avoid having chemotherapy first. Chemotherapy as Standard Mesothelioma Treatment First-line immunotherapy is not the typical mesothelioma treatment. Most mesothelioma patients have chemotherapy with Alimta (pemetrexed) before other treatments. Alimta is the … Continue reading First-Line Immunotherapy May Be Better Than Chemo for This Mesothelioma Subtype
Rare But Dangerous Side Effects of Opdivo for Mesothelioma
Australian researchers are warning of some rare but deadly side effects of Opdivo (nivolumab) for pleural mesothelioma. They have just published a case report of a mesothelioma patient on nivolumab, a drug often used to treat lung cancer. The patient developed swelling of the heart and other muscles. The swelling lasted for months, even after they stopped taking the drug. The case report details the healthcare teams’ effort to manage these potentially lethal side effects of Opdivo. They caution that other immune checkpoint inhibitors might cause similar complications. How Opdivo Fights Mesothelioma The primary treatment for mesothelioma is chemotherapy with pemetrexed (Alimta). Eventually, most patients stop responding to chemotherapy. At that point, doctors may turn to an immunotherapy drug like … Continue reading Rare But Dangerous Side Effects of Opdivo for Mesothelioma
Odds of Surviving Mesothelioma Equal in Rural and Urban Australia
Living in a city and having a better socioeconomic status does not necessarily increase the odds of surviving mesothelioma. That is the message from a 15-year Australian study of more than 300,000 cancer patients. Some studies suggest cancer survival rates are lower in rural areas. But that does not appear to be the case for mesothelioma in Australia. Unfortunately, the odds of surviving mesothelioma remain low no matter where a person lives. The Legacy of Asbestos in Australia Australia used to mine and export more asbestos than any other country. The mineral has been banned there since 2003, but Australian mesothelioma rates are still among the highest in the world. Asbestos fibers are biopersistent. Once they are embedded in the … Continue reading Odds of Surviving Mesothelioma Equal in Rural and Urban Australia
Mesothelioma Clinical Trial Results May Be Skewed by Narrow Inclusion Criteria
Australian researchers say too many mesothelioma clinical trial results are skewed because they do not include enough “real world” patients. By “real world patients”, they mean those who fit the profile of the typical mesothelioma patient. The researchers say some of the most important trials limit enrollment to younger people or those with few other health problems. They say that leaves out a lot of patients. It also makes mesothelioma clinical trial results less relevant in practice. How Clinical Trials Work Scientists typically test proposed new mesothelioma treatments on isolated cells in a lab first. If the results look promising, they will then run tests in animals to make sure the treatment is safe. Before a medicine receives approval for … Continue reading Mesothelioma Clinical Trial Results May Be Skewed by Narrow Inclusion Criteria
“My Name is Paul Kraus and I Have Survived Mesothelioma for Over 20 Years.”
In 1997 I was diagnosed with mesothelioma. The doctors gave me just a few short months to live...
But here I am, 20 years later, alive and well.
I wrote a book explaining how I became the longest living mesothelioma survivor in the world.
Today, I'd like to give you a copy for free because I want more people to survive this disease.
All you have to do is click the button below now. You will receive the book within 72 hours.
I wish you good health.
Sincerely,
"It has been over four years now and I can honestly say I am doing great. I highly recommend this book because it is inspirational and educational."
Get your free copy of
“Surviving Mesothelioma” Today!